Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus temozolomide as first-line therapy for pulmonary neuroendocrine tumors
ChiCTR2600116780Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Jan 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and temozolomide in typical pulmonary carcinoid tumor (TC) and Atypical Bronchial Carcinoid, sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoint: Progression-Free Survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
surufatinibtemozolomide
03
Conditions
typical pulmonary carcinoid tumor (TC)Atypical Bronchial Carcinoid
Beyond the preview
Go deeper on ChiCTR2600116780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116780.